Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI is a phase 2, interventional study registered as NCT07551414 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 38 participants, started 2026-05-30 and due to reach its primary completion in 2027-05-30. Interventions recorded: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy. Conditions listed: NSCLC (Non-small Cell Lung Carcinoma); Leptomeningeal Metastasis; EGFR-TKI Sensitizing Mutation; Zorifertinib. Primary outcome: Response Assessment in Neuro - Oncology Leptomeningeal Metastases (RANO - LM) criteria. Lung eligibility wording from the registry: "During the screening phase, subjects must be diagnosed with non-small cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and/or Exon 19Del)". Sites: China. No results are recorded here; the registry entry is the source.